Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Valasia V. Athyrou"'
Publikováno v:
Journal of clinical lipidology. 11(1)
Autor:
Dimokritos S. Demitriadis, Athanasios G. Kontopoulos, Vasilios G. Athyros, Athanasios A. Papageorgiou, Valasia V. Athyrou
Publikováno v:
Diabetes Care. 25:1198-1202
OBJECTIVE—This study evaluated the effect of a atorvastatin-fenofibrate combination on lipid profile, in comparison to each drug alone, in patients with type 2 diabetes and combined hyperlipidemia (CHL). RESEARCH DESIGN AND METHODS—A total of 120
Autor:
Elias O. Basayannis, Bodosakis R. Mercouris, Vasilios G. Athyros, Dimokritos S. Demitriadis, Athanasios N. Symeonidis, Valasia V. Athyrou, Athanasios A. Papageorgiou, Athanasios G. Kontopoulos
Publikováno v:
Current Medical Research and Opinion. 18:220-228
SummaryBackground: Atorvastatin is very effective in reducing plasma low-density lipoprotein cholesterol (LDL-C) levels. However, there is no long-term survival study that evaluated this statin.Patients−Methods: To assess the effect of atorvastatin
Autor:
Haris A. Hatzikonstandinou, Vasilios G. Athyros, Athanasios A. Papageorgiou, Valasia V. Athyrou, Athanasios G. Kontopoulos
Publikováno v:
Clinical Drug Investigation. 16:219-227
To investigate the effect of atorvastatin vs simvastatin on lipid profile and plasma fibrinogen in patients with hypercholesterolaemia.30 outpatients (25 men), with a median age of 51 years were studied. Eight patients had established coronary artery
Autor:
Vasilios G, Athyros, Athanasios A, Papageorgiou, Bodosakis R, Mercouris, Valasia V, Athyrou, Athanasios N, Symeonidis, Elias O, Basayannis, Dimokritos S, Demitriadis, Athanasios G, Kontopoulos
Publikováno v:
Current medical research and opinion. 18(4)
Atorvastatin is very effective in reducing plasma low-density lipoprotein cholesterol (LDL-C) levels. However, there is no long-term survival study that evaluated this statin.To assess the effect of atorvastatin on morbidity and mortality (total and
Autor:
Dimokritos S. Demitriadis, Athanasios G. Kontopoulos, Vasilios G. Athyros, Valasia V. Athyrou, AN Pehlivanidis, Athanasios A. Papageorgiou
Publikováno v:
Journal of cardiovascular risk. 9(1)
BACKGROUND Statin-fibrate combinations are very effective in the treatment of familial combined hyperlipidaemia (FCHL). Nonetheless, they have not been extensively used because of the fear of side effects. Thus, a therapeutic alternative is required
Autor:
Athyros VG; Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece., Papageorgiou A; Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece., Athyrou V; Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece., Karagiannis A; Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece.
Publikováno v:
Journal of clinical lipidology [J Clin Lipidol] 2017 Jan - Feb; Vol. 11 (1), pp. 306-307. Date of Electronic Publication: 2016 Nov 02.